Today, we published the 4th edition of our Life Science Research Tools (LSRT) market report. We forecast that the life science research tools market will reach $52B in 2017, and grow at ~5% p.a. to reach $64Bn in 2021. In this updated edition, we detail the market size, segmentation, growth, and trends of the LSRT industry from 2013 to 2021.

Our analysis confirms that within academia, growth will continue to be strong in emerging markets (e.g., China, India) offset by weakness in academic funding in developed countries (e.g., Japan, Europe). With that said, our analysis confirms that applied markets (such as non-IVD clinical / LDT’s, forensics or AgBio customers) might experience double digit growth for many technologies. This report evaluates which technologies are expected to capture (e.g., NGS, mass spectrometry) and lose (e.g., PCR) relative market share.Macro Drivers:

• Growth in APAC
• Strength in Biopharma and applied markets
• New instruments driving upgrade cycles and revenue growth

Macro Moderators:

• Funding pressure in the developing world
• Commoditization of some products
• Pricing Pressure
• Miniaturization

The fourth edition of this report provides an overview of the life sciences research tools market from 2013 to 2021. Life sciences research tools companies offer instruments, reagents and services to academic, BioPharma, applied market and (non-IVD) clinical customers. This market is consolidated, with top vendors including Agilent, Bio-Rad, Illumina, Life Technologies, MilliporeSigma, and Thermo Fisher representing the majority of sales; however, mid-size players (e.g., Luminex, NanoString) and smaller emerging players are highlighted and included in this report as well (e.g., Oxford Nanopore, Quanterix, Seahorse Biosciences).In this fourth edition, we updated our analysis to reflect the most current market sales and trends in five broad segments:

• Pure genomics technologies: PCR, qPCR, next generation sequencing (NGS) / third generation sequencing (3GS), CE sequencing, microarrays, molecular biology tools, digital PCR;
• Pure proteomics technologies: Antibodies, ELISA, protein production, western blots and protein microarrays;
• Cell biology technologies: discovery services, microscopy, basic cell biology reagents, flow cytometry, transfection and electroporation, media and sera, cell culture equipment, cells and tissues, whole cell analysis, high content imaging;
• Other analytical technologies: liquid chromatography, mass spectroscopy, structural analysis methods, in vivo study, spectroscopy, multiplex technologies, label free technologies;
• Other supplies and technologies: lab supplies and disposables, automation, glassware, sample preparation, LIMS, magnetic beads

For each of these 35 subsegments, we present an analysis detailing sales of instruments and reagents for 2013, 2017 and 2021. In addition, we detail market drivers (e.g., increased government funding in emerging markets) and moderators (e.g., pricing pressure for some technologies), market trends (e.g., shift of pharma interest from small molecule to large molecule drugs, interest in single cell analysis), a high-level end-customer breakdown (Academic, BioPharma and Applied markets customers) and key competitors.All data are based on manufacturer sales as publicly reported, and a total of 37 interviews with life sciences experts in academic, BioPharma and applied market laboratories conducted.The report is available at the following link: https://www.decibio.com/intelligence/market-reports/lsrt/

Author | Stephane Budel, PhD

Google+ | Linkedin | budel@decibio.comDr. Budel specializes in the market analysis of private to mid-cap companies with emerging to established technologies in the life science research tools and diagnostic spaces. He has deep genomics expertise, especially as it relates to clinical NGS. He has supported clients facing a broad range of challenging business issues, including R&D prioritization, evaluation of disruptive technologies, and commercial due diligences.Schedule a 15-minute call with Stephane today!Disclaimer: Companies listed above may be DeciBio Consulting clients and/or customers